We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

64 hedge funds and large institutions have $665M invested in 4D Molecular Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

23% more funds holding

Funds holding: 52 → 64 (+12)

10% more capital invested

Capital invested by funds: $602M → $665M (+$62.2M)

2.55% more ownership

Funds ownership: 55.09% → 57.64% (+2.6%)

0% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 13

Holders
64
Holders Change
+12
Holders Change %
+23.08%
% of All Funds
1.12%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
28
Increased
13
Reduced
13
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$24M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$18.9M
3
ACM
Aquilo Capital Management
California
+$12.4M
4
LCM
Laurion Capital Management
New York
+$9.67M
5
CC
Casdin Capital
New York
+$9.51M

Top Sellers

Rank Fund Capital Flow
1
SM
SB Management
United Arab Emirates
-$16.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.6M
3
PA
Perceptive Advisors
New York
-$6.88M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.27M
5
O
OrbiMed
New York
-$5.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
Viking Global Investors
1
Viking Global Investors
Connecticut
$171M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$55.9M -$13.6M -306,784 -19%
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$50.7M +$9.1M +205,486 +20%
ACH
4
ArrowMark Colorado Holdings
Colorado
$45.5M -$689K -15,555 -1%
BI
5
BVF Inc
California
$44.7M -$3.32M -75,000 -7%
CC
6
Casdin Capital
New York
$43.2M +$9.51M +214,799 +28%
BlackRock
7
BlackRock
New York
$23.7M +$24M +541,476 +9,134%
PA
8
Perceptive Advisors
New York
$19.3M -$6.88M -155,378 -26%
Vanguard Group
9
Vanguard Group
Pennsylvania
$19M +$18.9M +427,262 +4,273%
Alkeon Capital Management
10
Alkeon Capital Management
New York
$17.5M +$46.1K +1,041 +0.3%
OCA
11
Octagon Capital Advisors
New York
$16.4M +$22.6K +511 +0.1%
SM
12
SB Management
United Arab Emirates
$15.1M -$16.4M -369,824 -52%
Millennium Management
13
Millennium Management
New York
$14.5M -$449K -10,134 -3%
ACM
14
Aquilo Capital Management
California
$13.1M +$12.4M +280,886 +1,404%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$12.1M -$2.83M -63,932 -19%
LCM
16
Laurion Capital Management
New York
$12M +$9.67M +218,294 +376%
Morgan Stanley
17
Morgan Stanley
New York
$11.8M +$1.17M +26,441 +11%
CAM
18
Cormorant Asset Management
Massachusetts
$8.68M – – –
HA
19
HHLR Advisors
Cayman Islands
$6.83M -$2.99M -67,500 -30%
ABG
20
Ally Bridge Group
New York
$6.51M – – –
DM
21
Deerfield Management
New York
$6.51M – – –
Federated Hermes
22
Federated Hermes
Pennsylvania
$6.51M – – –
Geode Capital Management
23
Geode Capital Management
Massachusetts
$6.35M +$5.91M +133,518 +1,045%
State Street
24
State Street
Massachusetts
$4.63M +$4.73M +106,833 New
Wellington Management Group
25
Wellington Management Group
Massachusetts
$3.91M -$5.27M -118,928 -57%
1
2 3 4

FDMT Hedge Fund Activity: Q1 2021 in Review

64 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q1 2021, worth a combined $665M — up 10% from $602M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new FDMT positions and 16 closed out — a net gain of 12 holders — while 13 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $24M. The largest seller was SB Management, cutting an estimated $16.4M.

  • 64 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q1 2021, up from 52 in Q4 2020.
  • Funds reported $665M of 4D Molecular Therapeutics stock for Q1 2021, up 10% quarter-over-quarter.
  • 28 funds opened new 4D Molecular Therapeutics positions in Q1 2021 and 16 closed out, a net change of +12 holders.
  • The largest 4D Molecular Therapeutics buyer in Q1 2021 was BlackRock, an estimated $24M added.
  • The largest 4D Molecular Therapeutics seller in Q1 2021 was SB Management, an estimated $16.4M sold.

Based on aggregated 13F filings for Q1 2021.